Scroll

hyoscyamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
atropine derivatives	1402	101-31-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: hyoscyamine hydrobromide hyoscyamine (-)-Atropine (-)-Hyoscyamine L-Hyoscyamin L-Hyoscyamine l-Atropine hyoscyamine sulfate	The 3(S)-endo isomer of atropine. Molecular weight: 289.38 Formula: C17H23NO3 CLOGP: 1.30 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 49.77 ALOGS: -2.06 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

hyoscyamine hydrobromide
hyoscyamine
(-)-Atropine
(-)-Hyoscyamine
L-Hyoscyamin
L-Hyoscyamine
l-Atropine
hyoscyamine sulfate

The 3(S)-endo isomer of atropine.

Molecular weight: 289.38
Formula: C17H23NO3
CLOGP: 1.30
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 49.77
ALOGS: -2.06
ROTB: 5

Drug dosage:

Dose	Unit	Route
1.20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	3.56 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	57 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1869	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cholecystitis chronic	141.17	13.72	58	10095	9611	50585360
Biliary dyskinesia	72.77	13.72	25	10128	2525	50592446
Gallbladder disorder	60.05	13.72	39	10114	16703	50578268
Abdominal pain	44.90	13.72	126	10027	236102	50358869
Anticholinergic syndrome	37.61	13.72	14	10139	1781	50593190
Injury	36.49	13.72	47	10106	48878	50546093
Colitis ulcerative	32.50	13.72	27	10126	16827	50578144
Anxiety	31.05	13.72	92	10061	177514	50417457
Vision blurred	29.53	13.72	55	10098	78592	50516379
Emotional distress	28.71	13.72	32	10121	28631	50566340
Spleen congestion	26.94	13.72	6	10147	118	50594853
Cholelithiasis	23.03	13.72	33	10120	37940	50557031
Muscle spasms	22.84	13.72	66	10087	125487	50469484
Depression	22.80	13.72	79	10074	165344	50429627
Drug ineffective	22.33	13.72	87	10066	819246	49775725
Dizziness	21.73	13.72	131	10022	346238	50248733
Aortic valve calcification	19.87	13.72	6	10147	401	50594570
Diarrhoea	18.72	13.72	190	9963	588286	50006685
Biliary colic	17.93	13.72	10	10143	3249	50591722
Drug intolerance	17.77	13.72	11	10142	219093	50375878
Joint swelling	16.45	13.72	15	10138	245271	50349700
Gallbladder injury	16.32	13.72	7	10146	1287	50593684
Cystitis interstitial	16.14	13.72	7	10146	1322	50593649
Dry mouth	15.96	13.72	35	10118	56143	50538828
Abdominal distension	15.92	13.72	41	10112	72862	50522109
Abdominal pain upper	15.36	13.72	68	10085	159241	50435730
Haemorrhoids	15.30	13.72	19	10134	19034	50575937
Asthma	14.38	13.72	45	10108	89292	50505679
Blood testosterone decreased	14.00	13.72	3	10150	49	50594922
Dehydration	13.90	13.72	64	10089	152385	50442586

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abdominal pain	29.41	19.60	46	2474	135311	29436696
Faecal calprotectin abnormal	23.31	19.60	5	2515	200	29571807

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cholecystitis chronic	142.78	14.44	52	8711	9235	64480734
Biliary dyskinesia	67.06	14.44	21	8742	2351	64487618
Gallbladder disorder	65.19	14.44	36	8727	16994	64472975
Abdominal pain	38.43	14.44	111	8652	312264	64177705
Anticholinergic syndrome	37.52	14.44	14	8749	2655	64487314
Injury	37.44	14.44	42	8721	55950	64434019
Colitis ulcerative	34.35	14.44	27	8736	23001	64466968
Vision blurred	34.01	14.44	51	8712	90265	64399704
Emotional distress	31.15	14.44	31	8732	36007	64453962
Muscle spasms	28.90	14.44	61	8702	140962	64349007
Dizziness	27.97	14.44	124	8639	430039	64059930
Anxiety	27.82	14.44	75	8688	202574	64287395
Cholelithiasis	26.83	14.44	32	8731	45474	64444495
Dry mouth	21.16	14.44	33	8730	60385	64429584
Diarrhoea	20.16	14.44	167	8596	722537	63767432
Abdominal pain upper	19.39	14.44	60	8703	174970	64314999
Spleen congestion	17.17	14.44	5	8758	437	64489532
Depression	16.86	14.44	59	8704	183232	64306737
Gallbladder injury	16.06	14.44	6	8757	1142	64488827
Pain	15.98	14.44	129	8634	553382	63936587
Urinary tract infection	15.94	14.44	68	8695	231528	64258441
Aortic valve calcification	14.98	14.44	5	8758	685	64489284
Completed suicide	14.76	14.44	65	8698	224349	64265620

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A03BA03	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS BELLADONNA AND DERIVATIVES, PLAIN Belladonna alkaloids, tertiary amines
ATC	A03CB31	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Belladonna and derivatives in combination with psycholeptics
CHEBI has role	CHEBI:76924	plant metabolites
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D009184	Mydriatics
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D019141	Respiratory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Dysuria	indication	49650001
Sinus bradycardia	indication	49710005
Excessive salivation	indication	53827007
Gastrointestinal Radiography Adjunct	indication
Muscarine Toxicity	indication
Cholinesterase Inhibitors Toxicity	indication
Urinary Tract Irritation	indication
Irritable bowel syndrome	off-label use	10743008	DOID:9778
Diarrhea	off-label use	62315008
Urinary incontinence	off-label use	165232002
Neurogenic bladder	off-label use	398064005
Brain damage	contraindication	2470005
Ocular hypertension	contraindication	4210003	DOID:9282
Gastritis	contraindication	4556007	DOID:4029
Hypocalcemia	contraindication	5291005
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Hyperammonemia	contraindication	9360008
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Hepatic encephalopathy	contraindication	13920009	DOID:13413
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Cirrhosis of liver	contraindication	19943007	DOID:5082
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Glaucoma	contraindication	23986001	DOID:1686
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Glomerulonephritis	contraindication	36171008	DOID:2921
Acute hepatitis	contraindication	37871000
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypernatremia	contraindication	39355002
Hypovolemic shock	contraindication	39419009
Gastrointestinal ulcer	contraindication	40845000
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Body fluid retention	contraindication	43498006
Hyperactive behavior	contraindication	44548000
Uremia	contraindication	44730006	DOID:4676
Conduction disorder of the heart	contraindication	44808001
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Vitamin K deficiency	contraindication	52675005	DOID:11249
Nasal polyp	contraindication	52756005
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Ulcerative colitis	contraindication	64766004	DOID:8577
Blood coagulation disorder	contraindication	64779008	DOID:1247
Poisoning by phenobarbital	contraindication	64921004
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Sleep apnea	contraindication	73430006	DOID:0050847
Factor II deficiency	contraindication	73975000
Gastrointestinal hemorrhage	contraindication	74474003
Thrombotic thrombocytopenic purpura	contraindication	78129009	DOID:10772
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Chronic idiopathic constipation	contraindication	82934008
Hiatal hernia	contraindication	84089009	DOID:12642
Kidney disease	contraindication	90708001	DOID:557
Thyrotoxicosis	contraindication	90739004	DOID:7997
Hemophilia	contraindication	90935002
Myasthenia gravis	contraindication	91637004	DOID:437
Anemia due to enzyme deficiency	contraindication	111577008
Deficiency of glucose-6-phosphate dehydrogenase	contraindication	124134002	DOID:2862
Gastrointestinal obstruction	contraindication	126765001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Liver function tests abnormal	contraindication	166603001
Myocardial dysfunction	contraindication	233928007
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Sleep automatism	contraindication	247962006
Benign prostatic hyperplasia	contraindication	266569009
Dyspnea	contraindication	267036007
Edema	contraindication	267038008
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Drowsy	contraindication	271782001
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Cardiovascular event risk	contraindication	395112001
Gastric ulcer	contraindication	397825006	DOID:10808
Respiratory insufficiency	contraindication	409623005
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Porphyria	contraindication	418470004
Fever greater than 100.4 Fahrenheit	contraindication	426000000
Hypertensive urgency	contraindication	443482000
Severe dehydration	contraindication	450316000
Acute exacerbation of asthma	contraindication	708038006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.24	acidic
pKa2	9.26	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9	WOMBAT-PK	KEGG DRUG
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	9.30	WOMBAT-PK	KEGG DRUG
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	9.80	WOMBAT-PK	KEGG DRUG
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	9.90	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	9.20	WOMBAT-PK

External reference:

ID	Source
4018400	VUID
N0000189428	NUI
D00147	KEGG_DRUG
6835-16-1	SECONDARY_CAS_RN
4018398	VANDF
4018400	VANDF
4018402	VANDF
C0596004	UMLSCUI
CHEBI:17486	CHEBI
CHEMBL1331216	ChEMBL_ID
CHEMBL2106364	ChEMBL_ID
CHEMBL1257084	ChEMBL_ID
DB00424	DRUGBANK_ID
CHEMBL3989570	ChEMBL_ID
CHEMBL1697729	ChEMBL_ID
D064692	MESH_DESCRIPTOR_UI
3661	PUBCHEM_CID
PX44XO846X	UNII
1047802	RXNORM
20634	MMSL
4860	MMSL
4861	MMSL
4949	MMSL
6292	MMSL
71952	MMSL
72595	MMSL
d00985	MMSL
001727	NDDF
001728	NDDF
001729	NDDF
372757002	SNOMEDCT_US
387391003	SNOMEDCT_US
48899009	SNOMEDCT_US
56085009	SNOMEDCT_US
306-03-6	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
URELLE	HUMAN PRESCRIPTION DRUG LABEL	5	0037-6321	TABLET	0.12 mg	ORAL	Unapproved drug other	12 sections
Levsin	HUMAN PRESCRIPTION DRUG LABEL	1	0037-9001	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	Unapproved drug other	11 sections
URIBEL	HUMAN PRESCRIPTION DRUG LABEL	5	0076-0111	CAPSULE	0.12 mg	ORAL	unapproved drug other	20 sections
Hyophen	HUMAN PRESCRIPTION DRUG LABEL	5	0076-0901	TABLET	0.12 mg	ORAL	unapproved drug other	19 sections
Phosphasal	HUMAN PRESCRIPTION DRUG LABEL	5	0076-0902	TABLET	0.12 mg	ORAL	unapproved drug other	20 sections
Ustell	HUMAN PRESCRIPTION DRUG LABEL	5	0076-0903	CAPSULE	0.12 mg	ORAL	unapproved drug other	20 sections
Utira-C	HUMAN PRESCRIPTION DRUG LABEL	5	0178-0513	TABLET	0.12 mg	ORAL	unapproved drug other	12 sections
URIBEL	HUMAN PRESCRIPTION DRUG LABEL	5	0178-0740	CAPSULE	0.12 mg	ORAL	unapproved drug other	21 sections
ANASPAZ	HUMAN PRESCRIPTION DRUG LABEL	1	0225-0295	TABLET, ORALLY DISINTEGRATING	0.13 mg	SUBLINGUAL	unapproved drug other	21 sections
Belladonna Alkaloids with Phenobartbital	HUMAN PRESCRIPTION DRUG LABEL	4	0440-7183	TABLET	0.10 mg	ORAL	UNAPPROVED DRUG OTHER	14 sections
ED-SPAZ	HUMAN PRESCRIPTION DRUG LABEL	1	0485-0082	TABLET, ORALLY DISINTEGRATING	0.13 mg	ORAL	unapproved drug other	20 sections
UROGESIC BLUE	HUMAN PRESCRIPTION DRUG LABEL	4	0485-0151	TABLET, COATED	0.12 mg	ORAL	unapproved drug other	18 sections
UROGESIC BLUE	HUMAN PRESCRIPTION DRUG LABEL	4	0485-0151	TABLET, COATED	0.12 mg	ORAL	unapproved drug other	18 sections
UroAv-81	HUMAN PRESCRIPTION DRUG LABEL	5	15338-502	TABLET	0.12 mg	ORAL	unapproved drug other	18 sections
UroAv-B	HUMAN PRESCRIPTION DRUG LABEL	5	15338-503	CAPSULE	0.12 mg	ORAL	unapproved drug other	18 sections
Phenohytro	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0123	ELIXIR	0.10 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
Phenohytro	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0125	ELIXIR	0.10 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0162	ELIXIR	0.10 mg	ORAL	unapproved drug other	16 sections
Donnatal	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0423	ELIXIR	0.10 mg	ORAL	unapproved drug other	12 sections
Hyosyne	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0511	ELIXIR	0.13 mg	ORAL	unapproved drug other	11 sections
Hyosyne	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0514	ELIXIR	0.13 mg	ORAL	unapproved drug other	11 sections
Hyoscyamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-442	TABLET	0.13 mg	ORAL	Unapproved drug other	18 sections
RE-PB HYOS ELIXIR	HUMAN PRESCRIPTION DRUG LABEL	4	21695-594	ELIXIR	0.10 mg	ORAL	Unapproved drug other	11 sections
Belladonna Alkaloids with Phenobartbital	HUMAN PRESCRIPTION DRUG LABEL	4	21695-890	TABLET	0.10 mg	ORAL	Unapproved drug other	15 sections
Hyoscyamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-926	TABLET	0.13 mg	ORAL	Unapproved drug other	18 sections
QUADRAPAX	HUMAN PRESCRIPTION DRUG LABEL	4	21695-970	ELIXIR	0.10 mg	ORAL	Unapproved drug other	13 sections
Hyoscyamine Sulfate Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	33261-907	TABLET	0.38 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
Hyoscyamine	HUMAN PRESCRIPTION DRUG LABEL	1	39328-047	LIQUID	0.13 mg	ORAL	unapproved drug other	12 sections
Hyoscyamine	HUMAN PRESCRIPTION DRUG LABEL	1	39328-048	LIQUID	0.13 mg	ORAL	unapproved drug other	12 sections
Hyoscyamine Sulfate ODT	HUMAN PRESCRIPTION DRUG LABEL	1	42192-338	TABLET, ORALLY DISINTEGRATING	0.13 mg	ORAL	unapproved drug other	20 sections